Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique by Nadine F. Voelxen et al.
March 2016 | Volume 6 | Article 461
Original research
published: 07 March 2016
doi: 10.3389/fonc.2016.00046
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Michael Breitenbach, 
University of Salzburg, Austria
Reviewed by: 
Sergio Giannattasio, 
Consiglio Nazionale delle 
Ricerche, Italy 
Peter Maria Eckl, 
University of Salzburg, Austria
*Correspondence:
Wolfgang Mueller-Klieser  
mue-kli@uni-mainz.de
Specialty section: 
This article was submitted to 
Molecular and Cellular Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 15 December 2015
Accepted: 15 February 2016
Published: 07 March 2016
Citation: 
Voelxen NF, Walenta S, 
Proescholdt M, Dettmer K, Pusch S 
and Mueller-Klieser W (2016) 
Quantitative Imaging of D-2-
Hydroxyglutarate in Selected 
Histological Tissue Areas by a Novel 
Bioluminescence Technique. 
Front. Oncol. 6:46. 
doi: 10.3389/fonc.2016.00046
Quantitative imaging of D-2-
hydroxyglutarate in selected 
histological Tissue areas by a novel 
Bioluminescence Technique
Nadine F. Voelxen1 , Stefan Walenta1 , Martin Proescholdt2 , Katja Dettmer3 ,  
Stefan Pusch4 and Wolfgang Mueller-Klieser1*
1 Institute of Pathophysiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 
2 Department of Neurosurgery, University Hospital Regensburg, Regensburg, Germany, 3Institute of Functional Genomics, 
University of Regensburg, Regensburg, Germany, 4 Clinical Cooperation Unit Neuropathology, German Cancer Research 
Center (DKFZ), Heidelberg, Germany
Patients with malignant gliomas have a poor prognosis with average survival of less 
than 1 year. Whereas in other tumor entities the characteristics of tumor metabolism 
are successfully used for therapeutic approaches, such developments are very rare in 
brain tumors, notably in gliomas. One metabolic feature characteristic of gliomas, in 
particular diffuse astrocytomas and oligodendroglial tumors, is the variable content of 
D-2-hydroxyglutarate (D2HG), a metabolite that was discovered first in this tumor entity. 
D2HG is generated in large amounts due to various “gain-of-function” mutations in the 
isocitrate dehydrogenases IDH1 and IDH2. Meanwhile, D2HG has been detected in sev-
eral other tumor entities, including intrahepatic bile-duct cancer, chondrosarcoma, acute 
myeloid leukemia, and angioimmunoblastic T-cell lymphoma. D2HG is barely detectable 
in healthy tissue (<0.1 mM), but its concentration increases up to 35 mM in malignant 
tumor tissues. Consequently, the “oncometabolite” D2HG has gained increasing interest 
in the field of tumor metabolism. To facilitate its quantitative measurement without loss of 
spatial resolution at a microscopical level, we have developed a novel bioluminescence 
assay for determining D2HG in sections of snap-frozen tissue. The assay was verified 
independently by photometric tests and liquid chromatography/mass spectrometry. 
The novel technique allows the microscopically resolved determination of D2HG in a 
concentration range of 0–10 μmol/g tissue (wet weight). In combination with the already 
established bioluminescence imaging techniques for ATP, glucose, pyruvate, and lactate, 
the novel D2HG assay enables a comparative characterization of the metabolic profile of 
individual tumors in a further dimension.
Keywords: D-2 hydroxyglutarate, iDh mutations, bioluminescence imaging, oncometabolite, glioblastoma
Abbreviations: 2-HG, 2-hydroxyglutarate; 2-OG, 2-oxoglutarate; α-KG, alpha-ketoglutarate; AML, acute myeloid leukemia; 
ATP, adenosine triphosphate; D2HG, D-2-hydroxyglutarate; D2-HGDH, D-2-hydroxyglutarate dehydrogenase; EM-CCD, 
electron multiplying charge-coupled device; FMN, flavin mononucleotide; GC/MS, gas chromatography/mass spectrometry; 
HE, hematoxylin/eosin; HPLC, high performance liquid chromatography; IDH, isocitrate dehydrogenase; imBI, induced 
metabolic bioluminescence imaging; L2-HGDH, L-2-hydroxyglutarate dehydrogenase; LC/MS, liquid chromatography/mass 
spectrometry; NAD, nicotinamide adenine dinucleotide; NFO, NADH:FMN-oxidoreductase; RLU, relative light units; TCA, 
tricarboxylic acid; TET, ten-eleven translocation methylcytosine dioxygenase.
FigUre 1 | enzymatic reactions catalyzed by wild-type and mutant iDh enzymes modified after cairns and Mak (21). Top line: wild-type IDH1 and IDH2 
catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and CO2 while converting NAD+ to NADH + H+. Bottom line: mutant IDH1 and IDH2 reduce 
α-ketoglutarate to D-2-hydroxyglutarate (D2HG) while converting NADH + H+ to NAD+.
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inTrODUcTiOn
Heterozygous mutations in catalytic arginine residues of isoci-
trate dehydrogenases (IDHs) 1 and 2 (IDH1 and IDH2) have been 
identified during exome-sequencing studies of glioblastoma 
tumors in 2008 (1). These mutations can be found in approxi-
mately 75% of diffuse astrocytoma and oligodendroglioma 
tumors (2–4). Moreover, in 20% of acute myeloid leukemia 
(AML) (5, 6), 50% of chondrosarcoma (7, 8), 20% of intrahepatic 
cholangiocarcinoma (9), and 20% of angioimmunoblastic T-cell 
lymphoma, IDH1 or IDH2 are mutated as well (10). Regardless 
of the overall frequency, the type of IDH mutations differs in the 
described tumor entities: in astrocytoma and oligodendroglioma, 
more than 90% of all IDH mutations are of the IDH1R132H 
type (3), whereas the second most frequent type (about 4% of 
mutations) is IDH1R132C. It has been suggested recently that 
natural selection may act against the rare IDH1R132 mutations 
in human glioma due to the cytotoxicity of high levels of D-2-
hydroxyglutarate (D2HG) (11). Malignancies other than gliomas 
show different mutation spectra. In AML, the most frequent 
mutation is IDH2R140Q (6, 12); while in chondrosarcoma and 
intrahepatic cholangiocarcinoma, IDH1R132C represents the 
most frequent mutation (7, 9). In angioimmunoblastic T-cell 
lymphoma, mutations are found most frequently in IDH2 (10). 
2-HG has been described initially in the context of hereditary 
2-HG aciduria in 1980. 2-HG aciduria is caused by germline 
loss-of-function mutations in either D-2-hydroxyglutarate dehy-
drogenase (D2-HGDH) or L-2-hydroxyglutarate dehydrogenase 
(L2-HGDH) (13–17).
Interest in D-2-hydroxyglutarate (D2HG) as an “oncometabo-
lite” has gained momentum only recently. Tissue concentrations 
of D2HG, which is hardly detected in normal tissue (<0.1 mM), 
as high as 35 mM have been reported for malignant tumors (18). 
Such an extraordinary difference in metabolite concentration 
between tumor and normal tissues has been described previously 
only for lactate (19). At first, D2HG had been described solely in 
glioblastomas and AML. In the meantime, it has been detected in 
additional tumor entities, such as intrahepatic bile-duct cancer, 
and chondrosarcoma (20). The first review articles about D2HG 
suggested a common importance and role of this “oncometabo-
lite” in tumor progression of different entities (21–23). Elevated 
D2HG levels are produced in tumor cells that contain a “gain-of-
function” mutation of the IDH (21–23). From the three known 
isoforms of IDH, only somatic mutations in IDH1 and IDH2 have 
been reported to date to contribute to tumorigenesis. The IDH-
gene accounts for the most frequently mutated metabolic gene 
of all human tumors (24). As depicted in Figure 1, the wild-type 
enzyme (wild-type IDH1/IDH2) generates alpha-ketoglutarate 
(α-KG; also referred to as 2-oxoglutarate, 2-OG) while reduc-
ing NADP+ to NADPH + H+ and liberating CO2. The mutated 
enzyme (mutant IDH1/IDH2), in contrast generates D2HG while 
consuming NADPH. IDH1 and IDH2 are highly homologous, 
but they are distinct from the NAD+-dependent, heterotetrameric 
IDH3 enzyme that functions in the tricarboxylic acid (TCA) cycle. 
The physiological role of the NAD+-dependent IDH1/2 enzymes 
is not well characterized yet, but they are assumed to play dif-
ferent roles in the metabolism of glucose, fatty acids, glutamine, 
and to contribute to the maintenance of normal cellular redox 
status (21, 25). In vitro analyses indicate that cell membranes are 
impermeable for D2HG and the metabolite is barely taken up 
by cells in culture, compromising the direct investigation of the 
effects of IDH mutations and D2HG in cell culture systems (26). 
As a consequence, the function of D2HG is poorly understood.
The chiral molecule is very similar in its structure to the 
achiral 2-OG and is normally present at low levels in either its 
D- (or R-) enantiomeric forms. Recently, it has been demon-
strated that hypoxia induces selectively the production of the 
enantiomer L-2-hydroxyglutarate (L2HG) in mammalian cells 
due to promiscuous substrate usage primarily by lactate dehy-
drogenase A (27). However, in vitro and in vivo experiments have 
unraveled that the mutated IDH enzymes exclusively produce the 
D-enantiomeric form of 2-HG. These findings combined with the 
pattern of mutations in these genes support the concept that the 
production of D2HG by the mutant enzyme is responsible for 
driving tumor progression. Hence, D2HG has been described 
as an “oncometabolite” in glioma and AML (21). The molecular 
TaBle 1 | constituents of the enzyme solution employed for the quantitative determination of D2hg in cryosections using induced metabolic 
bioluminescence imaging (imBi).
constituent concentration Manufacturer
Phosphate buffer solution (containing KH2PO4 and Na2HPO4)  
(pH 7.0 at 20°C)
0.1 M Applichem, Darmstadt, Germany; Sigma-Aldrich, St.Louis, MO, USA
Dithiothreitol (DTT) 0.4 mM Sigma-Aldrich, St.Louis, MO, USA
Nicotinamide adenine dinucleotide (NAD) (free-acid grade) 20 mM Roche Diagnostics GmbH, Mannheim, Germany
Flavin mononucleotide (FMN) 0.25 M Applichem, Darmstadt, Germany
Decanal dissolved in methanol 6 mM Merck KGaA, Darmstadt, Germany; VWR international, Darmstadt, Germany
NAD(P)H-FMN-oxidoreductase (NFO) 3.6 units/mL Roche Diagnostics GmbH, Mannheim, Germany
Luciferase from Photobacterium fischeri 13.3 units/mL Roche Diagnostics GmbH, Mannheim, Germany
Hydroxyglutarate dehydrogenase (HGDH) 5.52 μg/μL kindly provided by S.Pusch from the lab of A.v.Deimling, DKFZ, Heidelberg, 
Germany
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mechanisms by which D2HG promotes tumorigenesis are not yet 
fully understood, but competitive inhibition of 2-OG-dependent 
dioxygenases, such as the DNA-modifying enzymes TET (Ten-
eleven translocation methylcytosine dioxygenase) and histone-
demethylases of the JmjC-type appears to play an important role 
(23). Furthermore, the recent observation that 2HG is capable of 
inhibiting ATP synthase and mTOR signaling and thus, tumor 
cell death under conditions of glucose limitations has provided 
a basis for understanding the better prognosis of IDH-mutant 
brain tumors (28).
It has been suggested that an elevated intratumoral level of 
2HG might serve as a suitable surrogate marker for the non-
invasive detection of IDH mutations by magnetic resonance 
spectroscopy (29). In body fluids such as plasma and urine and 
tissue extracts, total 2HG content has also been determined 
by liquid chromatography/mass spectrometry (LC/MS), gas 
chromatography/mass spectrometry (GC/MS) (29–31), and 
13C NMR spectroscopy (32). Combined with appropriate chiral 
selectors or chiral derivatizing agents, the aforementioned 
methods may also be used to determine the concentrations 
of the individual enantiomers (16, 33, 34). Furthermore, the 
stereospecificity of enzymes may be exploited for the selective 
determination of 2HG enantiomers, which carries the addi-
tional advantages of high-throughput and low instrumental cost 
(35). However, these methods require extraction of 2HG from 
tissues, whereby critical information with regard to the cellular 
source and potential tissue gradients of 2HG or its individual 
enantiomers is lost.
The aim of this study was to exploit the versatility of the 
bioluminescence technique currently used in our lab for the 
determination of ATP, glucose, pyruvate, and lactate for quantita-
tive D2HG imaging whereas serial sectioning and precise overlay 
of sections allows for signal acquisition in selected histological 
areas such as tumor tissue versus surrounding connective tissue 
or epithelium. The induced metabolic bioluminescence imaging 
(imBI) technique established in our laboratory uses specific 
enzymes as biochemical probes for the detection of metabolites. 
This specific biochemical reaction is coupled quantitatively via an 
enzyme chain to the light emission of bacterial luciferases (bio-
luminescence), thus, providing the necessary sensitivity to detect 
micromolar amounts of metabolite (36). For further information 
on the imBI technique refer to Sattler et al. (37), Walenta et al. 
(38), Walenta et al. (39), and Walenta et al. (36).
MaTerials anD MeThODs
assessment of specimens
With approval by the Ethics Committee of the University Medical 
Center Regensburg, Germany, and written informed consent 
by the patients, two frozen biopsies of human glioblastoma 
multiforme were provided by the Department of Neurosurgery 
at the University Hospital Regensburg. The frozen tissues were 
retrieved from liquid nitrogen and stored in an −80°C freezer for 
a minimum of 24 h. Crucial for obtaining accurate results is the 
immediate immersion of the biopsy specimens in liquid nitrogen. 
To prepare the biopsies for the imBi technique, tumor biopsies 
were sectioned at −20°C in a cryomicrotome into serial sections 
of 16 μm each for the detection of ATP, lactate, and glucose, and 
into sections of 20 μm for the detection of D2HG. The cryosec-
tions were then collected on cover slips and heated to 100°C for 
10 min to inactivate endogenous enzymes that might confound 
the measurements.
D2hg-Dependent Bioluminescence
Enzyme Solution
For the measurement of D2HG, we made use of the D2HGDH 
gene from Acidaminococcus fermentans (40), which had been 
previously cloned into a pASK-IBA7plus expression plasmid, 
expressed in E. coli and purified using the Strep®-tag affinity chro-
matography system (35). The constituents of the enzyme solution 
for D2HG-dependent bioluminescence measurements are listed 
in Table 1. For further information concerning expression and 
purification of D2-HGDH, see Balss et al. (35).
Calibration Standards
Standards of D2HG were obtained by dissolving D-2-
hydroxyglutaric acid disodium salt (Sigma-Aldrich, St Louis, 
MO, USA) in 50 mM MOPS-Cl buffer pH 7.4 (Sigma-Aldrich, St 
Louis, MO, USA). Then, an aliquot of this D-2-hydroxyglutaric 
acid MOPS-Cl solution was mashed with three parts of Tissue-
Tek® O.C.T. Compound (Sakura Finetek Europe B.V., Alphen 
aan den Rije, Netherlands) (4:1), mixed slowly for 30 min and 
afterwards frozen at −20°C until sectioning using a cryomi-
crotome. The section thickness was 16 or 20 μm. Standards used 
in former published studies using imBI were obtained from 
tissue homogenates (37) and the analysis of these homogenates 
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revealed the same results as the usage of Tissue Tek OCT and, 
therefore, Tissue Tek OCT compound was used.
Bioluminescence Measurement Procedure
For the bioluminescence imaging measurements, a cover glass 
containing a standard section with a known concentration or 
a section from an actual biopsy was placed upside down on a 
metal slide containing a casting mold filled with an excess amount 
(50 μL) of the above-mentioned enzyme solution. Thereby, the 
contact between the tissue sample and the enzyme solution 
initiates the bioluminescence reaction. The “reaction sandwich” 
was immediately placed on a thermostated stage of a microscope 
(Axiophot, Zeiss, Oberkochen, Germany) within a dark chamber. 
After 40 s of incubation time at 20°C, the bioluminescence was 
registered for a defined interval of time, determined by a prec-
edent kinetic control measurement. The emission of light was 
detected by a long distance precision lens (magnification 1.25×; 
Zeiss, Oberkochen, Germany) associated with a circular viewing 
field of 10 mm in diameter. A back-illuminated EM-CCD camera 
(iXonEM + DU-888; Andor Technology PLC, Belfast, UK) con-
nected to the microscope enables the registration of the low light 
bioluminescence intensity. The image signal is transferred to a 
computer for further analysis. By integration of the light emission 
intensities over a selected time frame, it is possible to obtain a 
density profile that represents the metabolite distribution across 
the tissue section analyzed. The measured profiles are calibrated 
in micromole of metabolite/gram of tissue (micromolar/gram; 
equivalent to millimolar/liter or millimolar in solution) and are 
displayed in a color-coded way. Based on the high water content 
of tumor cells of between 80 and 93% (41), 1 g of tumor tissue 
may be approximated by a volume of 1 mL. If we assume that 
this is approximately the volume of the solute for D2HG or 
other metabolites, a respective concentration of 1 μmol/mL or 
1 mmol/L (millimolar) is obtained. Serial sectioning and precise 
overlay of sections allows for signal acquisition in selected histo-
logical areas, such as in tumor tissue versus surrounding connec-
tive tissue or epithelium. For further methodological details, see 
Mueller-Klieser and Walenta (42), Sattler et al. (37), Walenta et al. 
(43), and Walenta et al. (36).
Image Analysis
The bioluminescence images of standard samples were analyzed 
for their mean light intensity using Andor iQ imaging software 
(Andor Technology PLC, Belfast, UK) and Excel (Microsoft, 
Redmond, WA, USA). After measuring the standard samples 
containing different amounts of D2HG, a calibration curve was 
generated that allowed the illustration of the two-dimensional 
substrate distribution of D2HG in tissue samples as well. The 
bioluminescence images obtained from tumor sections were 
transferred as 8-bit and 16-bit images to Adobe Photoshop CS5 
software (Adobe Systems Incorporated, San Jose, CA, USA), 
ImageJ (National Institute of Health, Bethesda, MD, USA), 
and Excel (Microsoft, Redmond, WA, USA). Using Photoshop 
software the bioluminescence images from tumor sections were 
overlaid with images of sequential sections stained with hema-
toxylin (Carl Roth GmbH, Karlsruhe, Germany) and eosine 
(Merck KGaA, Darmstadt, Germany) (HE) to analyze the data 
within selected histological areas, such as viable tumor regions, 
necrosis, or tumor-adjacent normal tissue. After overlaying 
the tissue samples, evaluation masks were drawn using a brush 
tool and a drawing-pad (BambooPad, Wacom Europe GmbH, 
Krefeld, Germany) in Adobe Photoshop CS5 imaging software. 
These evaluation masks were subsequentially loaded in ImageJ 
software and analyzed based on a semi-automated analysis 
method (Plug-in) called “tumor statistics,” which transfers the 
exact position and size of the evaluation mask to the 16-bit 
bioluminescence image and estimates the mean light intensity 
within this area and its SD automatically. The obtained data were 
transferred to Excel and OriginPro 8G Software (OriginLab 
Corporation, Northampton, MA, USA) for further statistical 
analysis. Representative images were calibrated in micromole 
of metabolite/gram of tissue in micromolar/gram (wet weight; 
equivalent to millimolar/liter in solution) in a color-coded man-
ner. Using appropriate standards, which are handled in exactly 
the same way as the tissue of interest, bioluminescence intensities 
can be transformed into absolute tissue concentrations of the 
respective metabolite, e.g., in micromoles/gram of tissue (micro-
molar/gram), which corresponds approximately to millimolar in 
solution. Additionally, while preparing the standard samples for 
calibration, the weights of the D2HG solution and the Tissue-Tek 
OCT compound are determined with an analytical balance to 
identify the actual concentration of the D2HG solution.
Fluorimetric D2hg assay
For the fluorimetric determination of D2HG, we used a slightly 
modified assay previously established by the lab of Andreas von 
Deimling at the DKFZ in Heidelberg, Germany (35). With the 
help of the expressed and purified D2HGDH enzyme, Balss 
et  al. had previously developed a fluorimetric assay, in which 
D2HGDH catalyzes the oxidation of D2HG to α-KG generating 
NADH + H+ in the process. The hydrogen from the accumulated 
NADH is then transferred by diaphorase to the non-fluorescent 
resazurin resulting in the production of fluorescent resorufin 
(44). The fluorimetric detection was performed with excitation 
and emission wavelengths of 540 ±  10  nm and 610 ±  10  nm, 
respectively, on a multiplate reader (35). This assay showed high 
accordance with LC/MS measurements. Therefore, we set up a 
standard series of 0–50 μM of D2HG and treated the standard 
samples (n  =  5 for each concentration) under two different 
conditions: one standard row was treated for 1 min with soni-
cation and was heat-autoclaved for 10 min. The other row was 
left untreated. The constituents of the D2HG-based fluorimetric 
solution are listed in Table 2. The standards and samples were 
analyzed immediately after excessive mixing at room temperature 
using the fluorimetric setting in the multiplate reader DTX 880 
(Beckman Coulter, Krefeld, Germany). Afterwards, a calibration 
curve was generated applying appropriate Excel and Origin 8G 
software.
Determination of 2hg by lc-Ms/Ms
Frozen tissue samples (#1385: 32.7  mg, #1586: 58.0  mg) were 
transferred to “Precellys-Keramik-Kit 1.4  mm” vials followed 
by 20  μL stable isotope-labeled internal standard solution 
(2,3,3-d3-2HG in water, 100 μM) and 1000 μL 80% methanol 
TaBle 2 | constituents of the enzyme solution employed for the quantitative determination of D2hg in solution by fluorimetrical analysis.
constituent concentration Manufacturer
HEPES buffer pH 8.0 100 mM Sigma-Aldrich, St.Louis, MO, USA
Nicotinamide adenine dinucleotide (NAD) (free-acid grade) 100 μM Roche Diagnostics GmbH, Mannheim, Germany
Diaphorase 0.1 units/μL MP Biomedicals, Heidelberg, Germany
Resazurin 5 μM Applichem, Darmstadt, Germany
Hydroxyglutarate dehydrogenase (HGDH) 5.52 μg/μL kindly provided by S.Pusch from the lab of A.v.Deimling, DKFZ, Heidelberg, Germany
FigUre 2 | stability of D-2-hydroxyglutarate (D2hg). Relative light units 
(RLU) as a function of D2HG concentration assayed photometrically via 
fluorescence assay. Mean values from quintuple measurements ± SD are 
shown for untreated (closed squares) and heat and mechanical treated (open 
circles) D2HG solutions. (Linear regression: y = 97767x + 863877; 
R2 = 0.997; n = 5; p < 0.00001).
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(MeOH:H2O, 80:20, v/v). The samples were homogenized twice 
at 6500 rpm for 20 s with an intermediate pause of 15 s using a 
Precellys homogenizer (Peqlab Biotechnologie GmbH, Erlangen, 
Germany). The homogenate was centrifuged at 9900 × g for 5 min 
at 4°C and the supernatant was transferred to a 1.5-mL glass 
vial. The pellet was washed consecutively with 500 and 300 μL 
80% methanol followed by a final wash with 300 μL water. All 
supernatants from one sample were combined and evaporated 
using an infrared vortex vacuum evaporator (CombiDancer, 
Hettich AG, Baech, Switzerland). The residues were reconsti-
tuted in 100 μL water and analyzed by HPLC-ESI-MS/MS using 
an Agilent 1200 SL HPLC (Boeblingen, Germany) and a 4000 
QTrap mass spectrometer (AB SCIEX, Darmstadt, Germany). 
A Discovery HS F5-3 HPLC column (15 cm × 2.1 mm, 3 μm; 
Supleco, Bellefonte, PA, USA) equipped with a Security Guard 
column (C18, Phenomenex, Aschaffenburg, Germany) was used 
with mobile phase A consisting of 0.1% formic acid in water 
(v/v) and acetonitrile as mobile phase B. Gradient elution started 
with an isocratic hold at 0% B for 6.5  min and a flow rate of 
200 μL/min followed by a linear increase to 100% B in 1.5 min 
using a flow rate of 350 μL/min, which was held for 2 min. For 
equilibration, the solvent was changed back to 0% B from 10 min 
to 10.1  min and held until 17  min. The flow rate was reduced 
back to 200 μL/min at 17.1  min and equilibrated for 1.9  min. 
The column was kept at 30°C, and an injection volume of 5 μL 
was used. The mass spectrometer was operated in negative mode 
using turbo ion spray employing the following parameters: gas 
1 and 2: 50 and curtain gas: 10 (arbitrary units).The ion spray 
voltage was set to −4500 V, the declustering potential to −40.0 V, 
the entrance potential to −10.0 V, the collision exit potential to 
−5 V, and the collision energy to −24 V. Detection was performed 
in multiple reaction monitoring (MRM) mode using the follow-
ing ion transitions: m/z 147.1 (M + H)+ to m/z 84.8 for 2HG 
and m/z 150.1 to m/z 87.8 for the deuterated internal standard. 
Quantification was achieved using a calibration curve with the 
area of 2HG normalized by the area of the stable isotope-labeled 
standard (deuterated 2HG).
statistics
Data were presented as the mean ± SD. For statistical analysis, 
OriginPro 8G Software (OriginLab Corporation, Northampton, 
MA, USA) and Microsoft Office Excel (Microsoft, Redmond, WA, 
USA) were used to perform Box Lucas equation for a non-linear 
regression curve and Student’s t-tests. For descriptive analysis, 
results were shown in boxplots (black bar in the middle: mean; 
boxes: 25 and 75% percentile; whiskers: SD). A p-value <0.05 was 
considered as being statistically significant.
resUlTs
stability of D-2-hydroxyglutarate
It was necessary to test the chemical stability of D2HG, since tissue 
sections have to be heated to inactivate endogenous enzymes and 
to fix them to the cover glass before bioluminescence imaging. 
In addition, the stability of D2HG values in tissue was tested by 
sonication of the standard samples. D2HG was, therefore, tested 
photometrically in aqueous solutions by the fluorimetric D2HG 
assay established by Balss et al. (35), following heat or sonication 
compared to untreated control samples. Figure 2 shows that heat-
autoclaving and sonication of D2HG solution has no degrading 
effect compared to untreated control samples (n =  5) and still 
revealed a concentration-dependent increase in relative light 
units (RLU) up to a D2HG concentration of 50 μM.
Biochemical Principle of D2hg-Dependent 
Bioluminescence
Biochemically, the principle of D2HG-dependent biolumi-
nescence is based on the luminescence of luciferase from 
Photobacterium fischeri. The substrate is first linked to the 
Nicotinamide adenine dinucleotide (NAD)/NADH + H+ redox 
FigUre 3 | Biochemical reaction scheme of D-2-hydroxyglutarate-
dependent bioluminescence. D2HGDH catalyzes the oxidation of 
D-2-hydroxyglutarate to α-ketoglutarate, while converting NAD+ to 
NADH + H+, which is linked to a light reaction via NFO and bacterial 
luciferase. Abbreviations: D2HGDH, D-2-hydroxyglutarate dehydrogenase; 
NFO, NADH:FMN-oxidoreductase.
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system via the specific enzyme. Next, the redox system is con-
nected to the bacterial luciferase Photobacterium fischeri through 
flavin mononucleotide (FMN). In principle, it is possible to 
measure any substance that can be linked quantitatively to NAD/
NADH + H+. Therefore, this fact was utilized in the present study 
to analyze the concentration and regional distribution of D2HG in 
cryosections. The reactions involved in the detection of D2HG are 
depicted in Figure 3. D-2-hydroxyglutarate (D2HG) is converted 
via the specific enzyme D-2-hydroxyglutarate-dehydrogenase 
(D2HGDH) into Alpha-ketoglutarate under the consumption 
of NAD+. The generated NADH is then linked to the light reac-
tion by the enzyme NADH:FMN-oxidoreductase (NFO), which 
converts NADH + H+ and FMN to FMNH2. The luciferase from 
Photobacterium fischeri, which is present in the mixture as well 
finally catalyzes the bioluminescent oxidation of FMNH2 and a 
long-chained aliphatic aldehyde. The aldehydes necessary for 
this reaction are long-chained fatty aldehydes. In the case of 
Luciferase from Photobacterium fischeri, as used in our assay, the 
long-chained fatty aldehyde is palmitic aldehyde (1-hexadecanal; 
C16H32O). In our assay, we use 5.69 mM decanal (C9H19CHO; 
caprinaldehyde) dissolved in methanol as long-chained aldehyde 
as substrate for the luciferase reaction. The light emission during 
this process is proportional to the initial D2HG concentration.
D2hg-Dependent Bioluminescence
Via bioluminescence imaging (imBI) of standard samples 
containing a known amount of D2HG from 0 mM to 10 mM in 
solution (equivalent to micromolar/gram wet weight of tissue), a 
calibration curve was generated (Figure 4C). Using a non-linear 
regression curve after the box/lucas model through the data 
points of the calibration curve allows the conversion of measured 
light intensities from unknown samples into absolute concentra-
tions in micromolar D2HG/gram tissue (wet weight) (BoxLucas: 
y = 7160*(1−0.83x); r2 = 0.768). As depicted in the inlay plot of 
Figure  4C regarding the D2HG concentrations between 0 and 
4 μmol/g, there was a linear regression detectable between the 
D2HG concentrations and the relative light intensities (Linear 
regression: y = 987.09x + 104.62; r2 = 0.984). The light emission 
was registered within a defined time interval determined by the 
reaction kinetics (Figure 4A). The reaction kinetics were obtained 
from recordings of a 10 mM D2HG standard section every 10 s 
for a period of about 4 min. The means of light intensities received 
from the camera software of every 10-s time slot are plotted 
against time. In this way, it is possible to obtain the reaction kinet-
ics from D2HG imBI and to define the time slots for incubation 
and measurement resulting in a protocol for the measurements 
of the standard calibration curve and the measurements of actual 
tissue biopsies. The area around the highest peak of light intensi-
ties of the reaction kinetics constitutes the time slot used for imBI 
measurement. The time until reaching the highest peak of light 
intensity is thereby standardized and routinely used as incubation 
and light integration time. Additionally, the reaction kinetics can 
be visualized more clearly using the accumulated light intensities 
obtained from the D2HG kinetics (see Figure 4B). Furthermore, 
it could be shown that the light intensity of imBI measurements 
was dependent on the thickness of the tissue sections as well as the 
temperature in the measurement chamber (Figure 5). Increasing 
the thickness of sections to 20 μm resulted in a significant aug-
mentation in light intensity of the standard curve at 2, 6, and 
8 μmol/g D2HG, compared to the light intensity of 16 μm tumor 
sections (Figure 5A). Heating of the measurement chamber to 
37°C resulted in a highly significant increase in light intensity at 
2, 4, 6, 8, and 10 μmol/g D2HG, compared to the light intensity at 
20°C (Figure 5B). We conclude from the data shown in Figure 5 
that by keeping section thickness and temperature constant, the 
light intensity generated by the D2HG bioluminescence assay is 
consistently proportional to the initial D2HG concentration, as 
prepared for the standard sections. The assay makes it possible to 
determine D2HG concentrations in frozen tissue sections in the 
range of 0–10 μmol/g of tissue (wet weight).
Quantification of D2hg in Tumor Biopsies 
of human glioblastoma Multiforme with 
Unknown iDh Mutation status
Tissue sections from human glioblastoma multiforme biopsies 
were used as tissues containing an unknown amount of D2HG 
to test our new bioluminescence imaging assay for the detection 
of D2HG. As depicted in Figure 6, serial sections from rapidly 
frozen tissue revealed a D2HG distribution (Figure 6D) that was 
remarkably similar to that of lactate (Figure 6C) concerning the 
color-coded tissue distribution (the regional overlays especially) 
(Figure 6E) in an adjacent section. Although regarding the abso-
lute counts, there was a marked difference between the D2HG 
and the lactate concentrations. In addition, bioluminescently 
determined concentrations of D2HG in two WHO grade IV 
glioblastoma biopsies were determined by means of LC-MS/
MS using internal calibration via analyte/stable isotope ratio. 
Therefore, samples from the same biopsies (#1385 containing low 
D2HG amounts; #1586 containing high D2HG amounts) were 
analyzed in parallel via D2HG-dependent imBI and LC-MS/
MS for their D2HG amount. As depicted in Figures 7A,B, the 
FigUre 4 | (a) Reaction kinetics of D2HG-dependent bioluminescence. Relative emission intensity of the D2HG-dependent bioluminescence mixture within 4 min. 
A 10 μmol/g standard section (20 μm) was used for measurement based on the D2HG enzyme mixture. The integration time is indicated in the figure.  
(B) Accumulated light intensities obtained from D2HG kinetics. The integration time is indicated in the figure. (c) D-2-hydroxyglutarate-dependent bioluminescence 
using D-2-hydroxyglutaric acid standard solutions mashed with Tissue-Tek® O.C.T. embedding medium at a temperature of 20°C. Representative calibration curve 
of D2HG-dependent bioluminescence from D-2-hydroxyglutaric acid standards: light intensity ± SD using 20 μm sections of frozen D-2-hydroxyglutaric acid 
standards (relative units) as a function of D2HG concentrations in micromolar/gram of tissue (wet weight; equivalent to mmol/L). BoxLucas: y = 7160*(1−0.83x); 
r2 = 0.768; p < 0.05; n = 3 for all concentrations. Insert plot displays the D2HG concentrations plotted against the light intensities in the range between 0 and 
4 μmol/g (linear regression: y = 987.09x + 104.62; r2 = 0.984; p < 0.05; n = 3 for all concentrations).
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amounts of D2HG detected by imBI of D2HG and LC-MS/MS 
agreed, with one of the specimens (#1385) containing a low level 
of D2HG (0.15 ± 0.08 μmol/g via D2HG imBI; 0.01 μmol/g via 
LC-MS/MS), while the other (#1586) contained a comparatively 
high amount of D2HG (2.10 ± 0.80 μmol/g via imBI; 0.43 μmol/g 
via LC-MS/MS). Not unexpectedly, the absolute amounts of 
D2HG differ between the two techniques by 93.4% for the speci-
mens containing low amounts of D2HG and by 79.6% for the 
specimens containing high amounts of D2HG. The results clearly 
demonstrated that these two biopsies contained largely different 
D2HG concentrations, which could be confirmed by LC-MS/MS. 
Obviously, a larger number of comparative measurements will be 
required to prove the reliability of the assay, but our preliminary 
data clearly demonstrates the great potential of bioluminescence 
imaging of D2HG and related metabolites in a tissue context.
DiscUssiOn
Induced metabolic bioluminescence imaging allows visualization 
of endogenous metabolite distributions in cryopreserved tissues. 
The method has been successfully applied among others to soy 
bean seedlings (45), 3D cell cultures (46), various organs, surgical 
wounds in laboratory animals (39), and a variety of experimental 
tumors and human tumor tissues (43). Currently, imBI is used 
for the detection of ATP, glucose, lactate, pyruvate, sucrose, 
and glycogen (42, 43, 45, 47). With the help of the purified 
FigUre 6 | imaging bioluminescence of aTP, lactate, and D2hg in a human WhO grade iV glioblastoma. (a) Hematoxylin and eosin (H&E) staining 
(10 μm) as well as color-coded distributions of concentrations of (B) ATP (16 μm); (c) lactate (16 μm), and (D) D-2-hydroxyglutarate (20 μm). There is an obvious 
similarity in the distribution pattern of lactate and D2HG. (e) Regional overlay of the analysis masks for lactate and D2HG. Tissue biopsies were kindly provided by 
Prof. Alf Giese from the Department of Neurosurgery, University Medical Center Mainz, Germany.
FigUre 5 | Bioluminescence intensity as a function of (a) section thickness and (B) temperature of the measurement chamber at different D2hg 
concentrations. Mean values from triplicate measurements ± SD are shown. Significant differences obtained by Student’s t-test are indicated by stars (*); p ≤ 0.05 
(*), p ≤ 0.001 (***).
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D2HGDH enzyme as described in Section “D2HG-Dependent 
Bioluminescence” (enzyme solution) in the Section “Material and 
Methods,” Balss et al. have previously developed a fluorimetric 
assay in which D2-HGDH catalyzes the oxidation of D2HG to 
α-KG generating NADH + H+ in the process. This assay showed 
high accordance with LC/MS measurements (35).
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Here, we have adapted this assay to the special requirements of 
our bioluminescence imaging technique and expanded its linear 
range to 10 mM in order to accommodate the millimolar con-
centrations of D2HG that can be found in IDH-mutant tumors 
(12, 18, 48). Furthermore, we could demonstrate that the D2HG 
molecule is insensitive to heating in the measurement range 
(Figure 2), which is required to inactivate endogenous enzymes 
that might confound imBI. In the course of optimizing imBI 
for the detection of D2HG, we also observed that an increase in 
enzyme concentration to 5 μg/μL and a concomitant reduction 
of the customary assay temperature of 37–20°C (Figure  5B) 
increased the reproducibility of multiple measurements of D2HG 
levels. Furthermore, we could show that the intensity of light 
emitted depended not only on the tissue content of D2HG, but 
also on the thickness of the cryosection (Figure 6A), underscor-
ing the known importance of preparing cryosections of equal 
thickness for measurement and calibration to obtain light emis-
sion that is proportional to the D2HG concentration in the tissue 
section (37). With the optimized assay, it thus became possible to 
determine in situ D2HG concentrations in frozen tissue sections 
up to 10 μmol/g tissue (wet weight).
Although designed as a study of feasibility, these preliminary 
results indicate that both techniques, LC-MS/MS and imBI, may 
identify corresponding tumors as high and low D2HG cancers, 
respectively. It is evident, however, that the analysis of a larger 
number of specimens is required to validate the novel technique 
with regard to its accurateness, reproducibility, and sensitivity on 
solid statistical grounds.
Further investigations will be needed to compare D2HG con-
centrations in normal and tumor tissues in a systematic way. A 
combination of bioluminescence imaging of ATP, lactate, glucose, 
pyruvate (37, 42), and D2HG will enable the characterization of the 
metabolic milieu of malignant and normal tissues more compre-
hensively in the future. As a further line of interest, the detection 
of elevated D2HG concentrations in different tumor entities may 
identify elevated D2HG levels as a surrogate marker, eventually in 
combination with the distribution of lactate, for tumor-relevant 
IDH1 and IDH2 mutations (3). Furthermore, D2HG detec-
tion might be of great interest in the development of selective 
inhibitors of mutant IDH1 and IDH2. In some neoplasms, such 
as AML, monitoring of D2HG might be an important parameter 
for remission or relapse of the disease (49). Additionally, D2HG 
from mutant IDH1 and IDH2 has been reported to alter several 
metabolic pathways, which could be shown in an in vitro over-
expression system. It could be demonstrated that levels of amino 
acids, glutathione metabolites, choline derivatives, and TCA 
cycle intermediates were altered in mutant IDH1- and IDH2-
expressing cells (50). Additionally, it has been demonstrated that 
2-HG concentrations in serum specimens collected from patients 
with gliomas do not necessarily correlate with IDH1/2 mutation 
status or tumor size (51). Thus, in situ determination of D2HG in 
biopsies or non-invasively by magnetic resonance spectroscopy is 
still required for the screening of IDH-mutant tumors that might 
benefit from alternative treatment regimens (21). Additionally, 
D2HG imaging may be a useful to distinguish between true 
tumor progression and treatment-related pseudoprogression in 
IDH-mutant gliomas (17).
Our newly established D2HG imBI method has the edge over 
the current standard methods applying IDH1R132H antibody 
staining and sequencing the IDH region, since with our method 
it is possible to detect all IDH mutations that can produce 2-HG 
and this is, additionally, possible with a spatial resolution that is 
otherwise only possible by the use of the IDH1R132H antibody.
In conclusion, we were able to develop a sensitive biolumi-
nescence imaging assay for the in  situ detection of D2HG in 
solid normal or tumor tissue of animal or human origin, thus 
providing a better insight into the distribution and effects of this 
oncometabolite in a tissue context.
FigUre 7 | (a) Imaging bioluminescence of D2HG in two WHO grade IV glioblastomas of initially unknown D2HG status. Mean values from tri-/quadruplicate 
measurements ± SD are shown for two biopsies, one containing low (#1385) and the other containing high levels of D2HG (#1586), respectively. Boxplot: mean 
(square), median (line), box (25 and 75% percentile), SD (whisker). (B) Corresponding mean values ± SD from triplicate measurements of 2HG by means of achiral 
LC-MS/MS using internal calibration via analyte/stable isotope ratio.
March 2016 | Volume 6 | Article 4610
Voelxen et al. D2HG-Imaging via Novel Bioluminescence Technique
Frontiers in Oncology | www.frontiersin.org
reFerences
1. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An inte-
grated genomic analysis of human glioblastoma multiforme. Science (2008) 
321:1807–12. doi:10.1126/science.1164382 
2. Balss JÃ, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 
Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 
(2008) 116:597–602. doi:10.1007/s00401-008-0455-2 
3. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type 
and frequency of IDH1 and IDH2 mutations are related to astrocytic and 
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta 
Neuropathol (2009) 118:469–74. doi:10.1007/s00401-009-0561-9 
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and 
IDH2 mutations in gliomas. N Engl J Med (2009) 360:765–73. doi:10.1056/
NEJMoa0808710 
5. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et  al. 
Recurring mutations found by sequencing an acute myeloid leukemia genome. 
N Engl J Med (2009) 361:1058–66. doi:10.1056/NEJMoa0903840 
6. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, et al. 
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid 
leukemia and confer adverse prognosis in cytogenetically normal acute 
myeloid leukemia with NPM1 mutation without FLT3 internal tandem 
duplication. J Clin Oncol (2010) 28:3636–43. doi:10.1200/JCO.2010.28.3762 
7. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and 
IDH2 mutations are frequent events in central chondrosarcoma and central 
and periosteal chondromas but not in other mesenchymal tumours. J Pathol 
(2011) 224:334–43. doi:10.1002/path.2913 
8. Arai M, Nobusawa S, Ikota H, Takemura S, Nakazato Y. Frequent IDH1/2 
mutations in intracranial chondrosarcoma: a possible diagnostic clue for 
its differentiation from chordoma. Brain Tumor Pathol (2012) 29:201–6. 
doi:10.1007/s10014-012-0085-1 
9. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et  al. 
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholan-
giocarcinoma identified through broad-based tumor genotyping. Oncologist 
(2012) 17:72–9. doi:10.1634/theoncologist.2011-0386 
10. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et  al. IDH2 
mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood (2012) 
119:1901–3. doi:10.1182/blood-2011-11-391748 
11. Pusch S, Schweizer L, Beck AC, Lehmler JM, Weissert S, Balss J, et al. D-2-
Hydroxyglutarate producing neo-enzymatic activity inversely correlates 
with frequency of the type of isocitrate dehydrogenase 1 mutations found in 
glioma. Acta Neuropathol Commun (2014) 2:19. doi:10.1186/2051-5960-2-19 
12. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. 
The common feature of leukemia-associated IDH1 and IDH2 mutations is a 
neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglu-
tarate. Cancer Cell (2010) 17:225–34. doi:10.1016/j.ccr.2010.01.020 
13. Chalmers RA, Lawson AM, Watts RW, Tavill AS, Kamerling JP, Hey E, et al. 
D-2-hydroxyglutaric aciduria: case report and biochemical studies. J Inherit 
Metab Dis (1980) 3:11–5. doi:10.1007/BF02312516 
14. Duran M, Kamerling JP, Bakker HD, van Gennip AH, Wadman SK. L-2-
Hydroxyglutaric aciduria: an inborn error of metabolism? J Inherit Metab Dis 
(1980) 3:109–12. doi:10.1007/BF02312543 
15. Steenweg ME, Jakobs C, Errami A, van Dooren SJ, Adeva Bartolomé MT, 
Aerssens P, et  al. An overview of L-2-hydroxyglutarate dehydrogenase 
gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat (2010) 
31:380–90. doi:10.1002/humu.21197 
16. Struys EA, Salomons GS, Achouri Y, Van Schaftingen E, Grosso S, Craigen 
WJ, et  al. Mutations in the D-2-hydroxyglutarate dehydrogenase gene 
cause D-2-hydroxyglutaric aciduria. Am J Hum Genet (2005) 76:358–60. 
doi:10.1086/427890 
17. Wahl DR, Venneti S. 2-Hydoxyglutarate: D/Riving pathology in gLiomaS. 
Brain Pathol (2015) 25:760–8. doi:10.1111/bpa.12309 
18. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. 
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 
(2009) 462:739–44. doi:10.1038/nature08617 
19. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key 
player in cancer. Cancer Res (2011) 71:6921–5. doi:10.1158/0008-5472.
CAN-11-1457 
20. Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, et al. MYC-
driven accumulation of 2-hydroxyglutarate is associated with breast cancer 
prognosis. J Clin Invest (2014) 124:398–412. doi:10.1172/JCI71180 
21. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mech-
anisms, models, and clinical opportunities. Cancer Discov (2013) 3:730–41. 
doi:10.1158/2159-8290.CD-13-0083 
22. Krall AS, Christofk HR. Cancer: a metabolic metamorphosis. Nature (2013) 
496:38–40. doi:10.1038/496038a 
23. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, 
(R)-2-hydroxyglutarate, and cancer. Genes Dev (2013) 27:836–52. doi:10.1101/
gad.217406.113 
24. Yang H, Xiong Y, Guan K. Metabolic alteration in tumorigenesis. Sci China Life 
Sci (2013) 56:1067–75. doi:10.1007/s11427-013-4549-2 
25. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev 
Cancer (2011) 11:85–95. doi:10.1038/nrc2981 
26. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydrox-
yglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxy-
genases. Cancer Cell (2011) 19:17–30. doi:10.1016/j.ccr.2010.12.014 
27. Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C, Judkins AR, et al. 
Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab (2015) 
22:304–11. doi:10.1016/j.cmet.2015.06.023 
28. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, et al. 2-Hydroxyglutarate 
inhibits ATP synthase and mTOR signaling. Cell Metab (2015) 22:508–15. 
doi:10.1016/j.cmet.2015.06.009 
29. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al. 
Detection of oncogenic IDH1 mutations using magnetic resonance spectros-
copy of 2-hydroxyglutarate. J Clin Invest (2013) 123:3659–63. doi:10.1172/
JCI67229 
30. Lombardi G, Corona G, Bellu L, Della Puppa A, Pambuku A, Fiduccia P, 
et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify 
patients with isocitrate dehydrogenase-mutated glioma. Oncologist (2015) 
20:562–7. doi:10.1634/theoncologist.2014-0266 
31. Sahm F, Capper D, Pusch S, Balss J, Koch A, Langhans CD, et al. Detection 
of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens 
by gas chromatography/mass spectrometry. Brain Pathol (2012) 22:26–31. 
doi:10.1111/j.1750-3639.2011.00506.x 
aUThOr cOnTriBUTiOns
Conceived and designed the experiments: NV, SW, and WM-K. 
Performed the experiments: NV, MP, KD, and SP. Analyzed 
the data: NV, MP, KD, SW, and WM-K. Contributed reagents/
materials/analysis tools: MP, KD, and SP. Wrote the paper: NV, 
SW, and WM-K.
acKnOWleDgMenTs
The authors wish to thank Prof. Dr. med. Andreas von Deimling and 
coworkers, in particular Dr. Joerg Balss and Dr. Stefan Pusch, from the 
Clinical Cooperation Unit Neuropathology of the DKFZ (German 
Cancer Research Center) in Heidelberg (Germany) for kindly pro-
viding us with D-2-hydroxyglutarate-dehydrogenase (D2HGDH) 
and Dr. Stefan Pusch for revising the manuscript. We also wish to 
thank Anette Denner-Seckert for technical support. Many thanks to 
Prof. Dr. Peter Oefner (Institute of Functional Genomics, University 
of Regensburg, Germany) for revising the manuscript.
FUnDing
This work was supported by grant nos. MU576/19-1 and KFO262 
from the German Research Foundation (DFG).
March 2016 | Volume 6 | Article 4611
Voelxen et al. D2HG-Imaging via Novel Bioluminescence Technique
Frontiers in Oncology | www.frontiersin.org
32. Pichumani K, Mashimo T, Baek HM, Ratnakar J, Mickey B, DeBerardinis 
RJ, et  al. Conditions for (13)C NMR detection of 2-hydroxyglutarate in 
tissue extracts from isocitrate dehydrogenase-mutated gliomas. Anal Biochem 
(2015) 481:4–6. doi:10.1016/j.ab.2015.04.017 
33. Cheng QY, Xiong J, Huang W, Ma Q, Ci W, Feng YQ, et al. Sensitive determi-
nation of onco-metabolites of D- and L-2-hydroxyglutarate enantiomers by 
chiral derivatization combined with liquid chromatography/mass spectrome-
try analysis. Sci Rep (2015) 5:15217–15217. doi:10.1038/srep15217 
34. Kaunzinger A, Rechner A, Beck T, Mosandl A, Sewell AC, Böhles H. Chiral 
compounds as indicators of inherited metabolic disease. Simultaneous 
stereodifferentiation of lactic-, 2-hydroxyglutaric- and glyceric acid by enan-
tioselective cGC. Enantiomer (1996) 1:177–82.
35. Balss J, Pusch S, Beck AC, Herold-Mende C, Krämer A, Thiede C, et  al. 
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta 
Neuropathol (2012) 124:883–91. doi:10.1007/s00401-012-1060-y 
36. Walenta S, Voelxen NF, Sattler UGA, Mueller-Klieser W. Localizing and 
quantifying metabolites in  situ with luminometry: induced metabolic 
bioluminescence imaging (imBI). Neuromethods (2014) 90:195–216. 
doi:10.1007/978-1-4939-1059-5_9 
37. Sattler UG, Walenta S, Mueller-Klieser W. A bioluminescence technique for 
quantitative and structure-associated imaging of pyruvate. Lab Invest (2007) 
87:84–92. doi:10.1038/labinvest.3700493 
38. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, et  al. 
Correlation of high lactate levels in head and neck tumors with incidence of 
metastasis. Am J Pathol (1997) 150:409–15. 
39. Walenta S, Schroeder T, Mueller-Klieser W. Metabolic mapping with bio-
luminescence: basic and clinical relevance. Biomol Eng (2002) 18:249–62. 
doi:10.1016/S1389-0344(01)00107-1 
40. Buckel W. The reversible dehydration of (R)-2-hydroxyglutarate to 
(E)-glutaconate. Eur J Biochem (1980) 106:439–47. 
41. Kiricuta IC Jr, Simplaceanu V. Tissue water content and nuclear magnetic 
resonance in normal and tumor tissues. Cancer Res (1975) 35:1164–7. 
42. Mueller-Klieser W, Walenta S. Geographical mapping of metabolites in bio-
logical tissue with quantitative bioluminescence and single photon imaging. 
Histochem J (1993) 25:407–20. doi:10.1007/BF00157805 
43. Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: 
potential basis of a metabolic classification in clinical oncology. Curr Med 
Chem (2004) 11:2195–204. doi:10.2174/0929867043364711 
44. Candeias LP, MacFarlane DPS, McWhinnie SLW. The catalysed NADH 
reduction of resazurin to resorufin. J Chem Soc Perkin Trans (1998) 2:2333–4. 
doi:10.1039/A806431H 
45. Borisjuk L, Walenta S, Rolletschek H, Mueller-Klieser W, Wobus U, Weber 
H. Spatial analysis of plant metabolism: sucrose imaging within Vicia faba 
cotyledons reveals specific developmental patterns. Plant J (2002) 29:521–30. 
doi:10.1046/j.1365-313x.2002.01222.x 
46. Walenta S, Doetsch J, Mueller-Klieser W, Kunz-Schughart LA. Metabolic 
imaging in multicellular spheroids of oncogene-transfected fibroblasts. 
J Histochem Cytochem (2000) 48:509–22. doi:10.1177/002215540004800409 
47. Levin M, Bjornheden T, Evaldsson M, Walenta S, Wiklund O. A biolumines-
cence method for the mapping of local ATP concentrations within the arterial 
wall, with potential to assess the in vivo situation. Arterioscler Thromb Vasc 
Biol (1999) 19:950–8. doi:10.1161/01.ATV.19.4.950 
48. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, 
et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute 
myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp 
Med (2010) 207:339–44. doi:10.1084/jem.20092506 
49. Pollyea DA, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, et  al. 
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient 
responses, minimal residual disease and correlations with methylcytosine and 
hydroxymethylcytosine levels. Leuk Lymphoma (2013) 54:408–10. doi:10.310
9/10428194.2012.701009 
50. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling 
the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular 
metabolome. Proc Natl Acad Sci U S A (2011) 108:3270–5. doi:10.1073/
pnas.1019393108 
51. Capper D, Simon M, Langhans CD, Okun JG, Tonn JC, Weller M, et  al. 
2-Hydroxyglutarate concentration in serum from patients with gliomas does 
not correlate with IDH1/2 mutation status or tumor size. Int J Cancer (2012) 
131:766–8. doi:10.1002/ijc.26425 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Voelxen, Walenta, Proescholdt, Dettmer, Pusch and Mueller-
Klieser. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
